Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Escalating venetoclax dose was safe in relapsed CLL

Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

Key clinical point: Quick ramp up of venetoclax dosing in relapsed CLL appears safe.

Major finding: All patients reached the target dose of venetoclax, with only two cases of manageable clinical tumor lysis syndrome.

Study details: Retrospective analysis of outcomes for 15 patients with CLL who relapsed after treatment with a B-cell receptor signaling inhibitor.

Disclosures: The study was internally funded. Dr. Awan reported research funding from Gilead, Pharmacyclics, AbbVie, and Janssen.

Source: Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

Read the article.

Citation:

Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

This Week's Must Reads

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018

Must Reads in Aggressive Lymphomas

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NH, Advani R et al. N Engl J Med. 2018;379:1711-21

Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025

Complications in EPOCH-R versus R-CHOP, David RJ et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 29. doi: 10.1016/j.clml.2018.08.014

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85